Company profile
Gilead Sciences, Inc. is a biopharmaceutical innovator dedicated to the research, development, and global commercialization of medicines that address significant unmet medical needs across the United States, Europe, and other international regions. Its extensive product lineup includes leading treatments for HIV/AIDS, such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla. For COVID-19, the company provides Veklury, an injectable therapy for intravenous administration. Gilead also offers a robust portfolio of drugs combating various liver diseases, specifically Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, it supplies therapeutic solutions for patients with hematological, oncological, and cell-based conditions, including Yescarta, Tecartus, Trodelvy, and Zydelig. Beyond these, its offerings extend to Letairis, an oral medication for pulmonary arterial hypertension; Ranexa, another oral formulation for chronic angina; and AmBisome, a liposomal agent designed to treat serious invasive fungal infections. Incorporated in 1987 and headquartered in Foster City, California, Gilead Sciences actively engages in collaboration agreements with various entities, such as Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc.
- CEO
- Daniel O'Day
- Employees
- 17,000
- IPO date
- 03 Jan 2000
- ISIN
- US3755581036
